JAK

The JAK-STAT signalling pathway is a chain of interactions between proteins in a cell, and is involved in processes such as immunity, cell division, cell death and tumour formation. There are 4 JAK proteins: JAK1, JAK2, JAK3 and TYK2. JAKs contains a FERM domain (approximately 400 residues), an SH2-related domain (approximately 100 residues), a kinase domain (approximately 250 residues) and a pseudokinase domain (approximately 300 residues). The kinase domain is vital for JAK activity, since it allows JAKs to phosphorylate (add phosphate groups to) proteins.

Cat. No.	Product name	CAS No.	Purity
T12266	Ilginatinib	1239358-86-1	99.43%
T12266	Ilginatinib (NS-018) is a highly active and orally bioavailable inhibitor of JAK2.
T22416	RO495	1258296-60-4	99.4%
T22416	RO495 (CS-2667), a potent inhibitor of TYK2, inhibits TYK2 with IC50 of 1.5nM as tested in cell-based pharmacological assays
T2709	TAK-901	934541-31-8	99.39%
T2709	TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others....
TQ0061	CHZ868	1895895-38-1	99.38%
TQ0061	CHZ868 is a type II JAK inhibitor with potential antitumor activity that reverses the persistence of type I JAK inhibitors and can be used to study leukemia.
T8742	G5-7	939681-36-4	99.37%
T8742	JAK2 inhibitor G5-7 (JAK2 inhibitor G5-7) is an orally active JAK2 inhibitor, selectively inhibits JAK2–mediated phosphorylation and activation of EGFR (Tyr1068)...
T4210	SAR-20347	1450881-55-6	99.35%
T4210	SAR-20347 is an inhibitor of TYK2, JAK1/2/3 (IC50: 0.6/23/26/41 nM).
T6104	Cerdulatinib hydrochloride	1369761-01-2	99.23%
T6104	Cerdulatinib hydrochloride (PRT2070 hydrochloride) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for ...
T3072	XL019	945755-56-6	99.23%
T3072	XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, 100 fold selectivity over JAK1.
T3076	GLPG0634 analog	1206101-20-3	99.22%
T3076	GLPG0634 analog (GLPG0634 analogue) is a specific JAK1 inhibitor with IC50 of 10/28/810/116 nM for JAK1/2/3 and TYK2, respectively.
T78607	JAK-STAT-IN-1	1236666-76-4	99.21%
T78607	JAK-STAT-IN-1 is a specific JAK-STAT inhibitor indicated for the study of autoimmune diseases.
T1985	WHI-P154	211555-04-3	99.19%
T1985	WHI-P154 (Jak3 inhibitor ii) is a potent JAK3 inhibitor.
T6914	Oclacitinib maleate	1640292-55-2	99.17%
T6914	Oclacitinib maleate (PF-03394197 maleate) is a novel inhibitor of JAK family members with IC50 ranging from 10 to 99 nM and JAK1-dependent cytokines with IC50 ra...
T21503	(E/Z)-Zotiraciclib	937270-47-8	99.12%
T21503	(E/Z)-Zotiraciclib ((E/Z)-TG02) inhibits CDK2, JAK2, and FLT3 effectively with IC50s of 13, 73, and 56 nM, respectively.
T9195	SHR0302	1445987-21-2	99.11%
T9195	SHR0302 (ARQ252) is a JAK inhibitor that binds JAK1 with stronger affinity than others (Selectivity for JAK1 is more than 10 times for JAK2, 77 times for JAK3, 4...
T2156	WP1066	857064-38-1	99.07%
T2156	WP1066 is a inhibitor of JAK2 (IC50: 2.30 μM) and STAT3 (IC50: 2.43 μM) in HEL cells; shows activity to JAK2, STAT3/5, and ERK1/2, not JAK1 and JAK3. WP1066 has ...
T3998	Itacitinib	1334298-90-6	99.01%
T3998	Itacitinib (INCB039110) is an orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1) with potential antineoplastic activity.
T3065	TG101209	936091-14-4	99%
T3065	TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM.
T12427	Brepocitinib P-Tosylate	2140301-96-6	98.99%
T12427	Brepocitinib P-Tosylate (PF-06700841 P-Tosylate) is a potent dual inhibitor of Janus kinase 1 (JAK1) and TYK2 (IC50s of 17 nM and 23 nM, respectively).
T9251	Fedratinib hydrochloride hydrate	1374744-69-0	98.96%
T9251	Fedratinib hydrochloride hydrate (SAR 302503 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor.
T4657	WHI-P97	211555-05-4	98.91%
T4657	WHI-P97 is a rationally designed potent inhibitor of JAK-3. IC50 value: Target: JAK3 Treatment of mast cells with WHI-P97 inhibited the translocation of 5-lipoxy...